Tempus AI buys Personalis at $16.25, adds stock floor

Tempus AI (TEM) said in a Monday filing it agreed to acquire Personalis (PSNL) in a cash-and-stock merger valuing the target at $16.25 a share, turning healthcare-AI consolidation into a signed public-markets deal. For investors, the immediate issue is narrower than the strategic pitch: can Tempus use its own stock as currency without leaving Personalis holders exposed to the buyer’s share swings?

In the agreement disclosed in Tempus’s 8-K, Personalis holders can elect cash or stock. A stock election carries a $48.42 Tempus floor and a 0.3356 exchange-ratio floor, according to the filing. In practical terms, the structure is more guarded than a floating share swap. Tempus keeps equity in the mix. The floor, though, limits how far a weaker Tempus share price can reduce the stated value offered to Personalis investors.

The terms land in a changed market for public precision-medicine groups. Tempus reported $1.271789 billion of annual revenue, up 36.1 per cent year over year. Meanwhile, Personalis said in its own 8-K that annual revenue was $69.648 million, down 24.9 per cent. With Tempus valued at about $8.69 billion against Personalis at roughly $1.40 billion, the buyer is using scale and a stronger public-market rating to roll up a smaller peer.

Reading the exchange ratio

Personalis brings diagnostics and genomic-testing infrastructure to a buyer with a larger public-market base. Stock-funded consolidation can look simple from a distance. This agreement is more textured. The transaction says as much about data ownership and lab workflow as it does about AI models. Management’s cash-and-stock mix implies Tempus views its equity as usable currency, though only with a guardrail that acknowledges a volatile share price.

The strategic pitch fits how drugmakers have begun to discuss AI in research and diagnostics. In June, AstraZeneca chief executive Pascal Soriot told CNBC that Tempus-linked AI work is being judged less on novelty and more on productivity.

“The value of AI in our industry is productivity improvement.”
Pascal Soriot, AstraZeneca CEO, to CNBC

For investors weighing the merger, Soriot’s comment points to the commercial test. Personalis adds testing capacity and genomics data in a market where buyers want assets that can connect clinical data to drug discovery, diagnostics and care pathways. Those links are easy to describe and hard to monetize.

A Nature paper on medical-genome standards published this month argued that genomic diagnostics still need better-aligned resources and standards to build confidence across research and clinical use. Viewed through that lens, Tempus is buying a more complex operating base rather than a finished software-margin story. Reimbursement, data quality and clinical adoption will still decide whether scale produces lasting returns.

Approvals still ahead

Filings from both companies describe a signed transaction with standard deal protections. Tempus and Personalis disclosed board approvals, no-shop restrictions and a reciprocal $76.8 million termination fee. Personalis’s filing said Merck Sharp & Dohme LLC, which controls about 13 per cent of the company’s voting power, signed a voting agreement in support of the deal. The voting agreement lowers the odds of a competing deal. It does not remove closing conditions.

Before the deal can close, Tempus still needs regulatory clearance under the Hart-Scott-Rodino Act, SEC review of the S-4 registration statement and shareholder approval. The merger documents set an April 20, 2027, outside date. A runway that long leaves Tempus exposed to market moves in its own shares while approvals are pending.

Shareholders now have a concrete AI-healthcare test, not another product announcement. Tempus is paying cash, offering stock and placing a floor under that stock while betting it can extract more value from Personalis than the target could alone. Trading in Tempus shares will start marking that bet well before the merger closes.